Moreover, metformin also sensitizes cholangiocarcinoma cells to chemotherapeutic agents such as sorafenib, 5-fluorouracil, and arsenic trioxide by regulating the AMPK/mTOR/HIF-1α/MRP1 pathway and ERK [48,49]. This evidence concerns the gene MTOR and cholangiocarcinoma.